Peptides is a topic tracked in our intelligence system with 7 linked articles.
Bipartisan lawmakers are pressing the FDA to close a regulatory loophole that allows gray-market importation of knockoff retatrutide, Eli Lilly's investigational triple-agonist obesity drug.
Trump administration health officials are advancing a plan to let specialty pharmacies compound certain peptides — a largely unregulated injection class championed by HHS Secretary Robert F. Kennedy Jr. — signaling a permissive shift in federal drug-compounding policy with direct market consequences for compounders, telehealth prescribers, and wellness/pharma players.
FDA peptide reclassification could unlock pharmacy compounding for peptides, signaling regulatory tailwinds and potential revenue upside for telehealth/pharmacy players; timeline and safety risk remain uncertain.
TechCrunch Mobility blends a high-profile EV critique (Ferrari Luce) with regulatory and funding dynamics in mobility and AI, anchored by hard data points like AV registrations, deal sizes, and regulatory shifts.
US Black-founded startups have raised a record $643M in 2026 year-to-date amid a funding downturn, driven by a few large rounds, while regulatory shifts around peptides (FDA advisory committee in July 2026) could reshape the opportunity set.
TechCrunch dissectes Enhanced Games and the wider peptide/health enhancement trend, highlighting a $1.2B IPO, a $50M venue, and high-prize, high-risk athletic and regulatory dynamics driven by Silicon Valley backing.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.